内皮细胞乙酸摄取代谢增强通过组蛋白乙酰化促进肿瘤血管生成与免疫抑制
该研究探讨乙酸-乙酰化轴是否在肿瘤内皮细胞(TECs)中被劫持以调控肝细胞癌(HCC)进展。研究使用临床标本、原代内皮细胞、细胞系及多种小鼠模型系统解析内皮乙酸-乙酰化轴及其对恶性表型和抗癌治疗的影响,发现TECs中乙酸转运体MCT1、代谢酶ACSS2及H3K27ac升高,乙酸与肿瘤血管生成正相关,靶向该代谢-表观遗传轴可增强HCC治疗并增敏免疫治疗。
要点
- TECs中MCT1、ACSS2和H3K27ac升高,乙酸与肿瘤血管生成正相关。
- 乙酸或肝癌条件培养基增加内皮H3K27ac和EC迁移,抑制MCT1或ACSS2可减弱。
- ACSS2抑制与抗PD-1协同减轻免疫抑制、抑制血管生成和肿瘤进展。
核心结论
- 肝脏乙酸积累及TECs中MCT1/ACSS2上调驱动内皮表观遗传重塑,促进血管生成、免疫抑制和HCC进展。
- 靶向该代谢-表观遗传轴是增强HCC治疗和增敏免疫治疗的新方法。
研究设计与样本
- 使用临床标本、HCC原代TECs或非肿瘤肝组织原代NECs、EC细胞系及多种小鼠模型系统解析内皮乙酸-乙酰化轴。
主要发现
- 与NECs相比,TECs中乙酸转运体MCT1、代谢酶ACSS2和H3K27ac升高。
- 乙酸在肿瘤及周围实质中高度富集,并与肿瘤血管生成正相关。
- 乙酸或肝癌条件培养基增加内皮H3K27ac和EC迁移,抑制MCT1或ACSS2可减弱。
- 乙酸处理的ECs(而非单独乙酸)驱动CD8+ T细胞耗竭和Treg扩增。
- 小鼠肝癌同种移植模型中,乙酸给药增加TECs中H3K27ac,驱动血管生成、肿瘤生长和转移,同时减少CD8+ T细胞并扩增Tregs。
关键数值与推荐
- 药理抑制ACSS2、EC靶向simACSS2脂质体和AAV-TIE2-shmACSS2均降低TECs中H3K27ac、抑制血管生成、增加CD8+ T细胞并减少Tregs。
- ACSS2抑制与抗PD-1协同减轻免疫抑制、抑制血管生成并抑制肿瘤进展。
临床怎么用
- 靶向内皮乙酸-乙酰化轴(如抑制ACSS2)可能增强HCC治疗并增敏免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acetate is the metabolic precursor of acetyl-coenzyme A (CoA), fuelling histone acetylation. OBJECTIVE: We aimed to investigate whether the acetate-acetylation axis is hijacked in tumour endothelial cells (TECs) to govern hepatocellular carcinoma (HCC) progression. DESIGN: The endothelial acetate-acetylation axis and its impact on malignant phenotypes and anticancer therapy were systematically dissected using clinical specimens, primary endothelial cells (ECs) from HCC (tumour endothelial cells, TECs) or non-tumour liver tissues (non-tumour endothelial cells, NECs), EC lines and diverse mouse models. RESULTS: Compared with NECs, TECs showed elevation of acetate transporter (monocarboxylate transporter 1, MCT1), metabolic enzyme ACSS2 and H3K27ac. Acetate was highly enriched within tumour and surrounding parenchyma, and correlated positively with tumour angiogenesis. Functionally, acetate or hepatoma-conditioned media increased endothelial H3K27ac and EC migration, which were attenuated by inhibiting MCT1 or ACSS2. Notably, acetate-treated ECs, but not acetate alone, drived CD8+ T cell exhaustion and regulatory T cell (Treg) expansion. In mouse hepatoma allograft models, acetate administration increased H3K27ac levels in TECs, driving angiogenesis, tumour growth and metastasis, while reducing CD8+ T cells and expanding Tregs. Mechanistically, acetate orchestrated pro-angiogenic and immunosuppressive transcriptional programmes in ECs via histone acetylation. Therapeutically, pharmacological ACSS2 inhibition, EC-targeting simACSS2-liposomes and adeno-associated virus (AAV)-TIE2-shmACSS2 all decreased H3K27ac levels in TECs, inhibited angiogenesis, increased CD8+ T cells and reduced Tregs. Crucially, ACSS2 inhibition synergised with anti-programmed cell death protein 1 (PD-1) to alleviate immunosuppression, curb angiogenesis and suppress tumour progression. CONCLUSION: Hepatic acetate accumulation and concomitant MCT1/ACSS2 upregulation in TECs drives endothelial epigenetic remodelling, thus fuelling angiogenesis, immunosuppression and HCC progression. Targeting this metabolic-epigenetic axis represents a novel approach to potentiate HCC therapy and sensitise immunotherapy.
引用
- Chen JY, Ji YC, Wu CH, et al. Enhanced acetate uptake and metabolism in endothelial cells promote tumour angiogenesis and immunosuppression by increasing histone acetylation. Gut. 2026. PMID: 42538152. doi:10.1136/gutjnl-2026-338754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。